INVEST IN THE FUTURE OF CARDIAC TECHNOLOGY
Secure your spot in this pioneering heart surgery development.
MEDICAL 21 AIMS TO REVOLUTIONIZE HEART DISEASE TREATMENT
Nearly 1 million people undergo heart bypass each year – the surgery is painful, invasive, and recovery times are drawn out. Medical 21 aims to replace the current procedure with their transformative artificial biocompatible artery technology, MAVERICS.
Fewer Cuts. Less Pain.
Our artificial arteries can remove the need for intrusive cuts and removal of veins from legs, arms, and breast.
50% Less time in Surgery
We can shorten surgical time for patients and allow hospitals to more efficiently serve more patients.
Shorter Rehab
We can alleviate pain for patients by removing the healing process connected to the intrusive cut.
Greater Accessibility
We can make bypass available for diabetics, amputees, and others previously ineligible for surgery.
Invest in a team that has Pioneered Heart Tech for more than 50 years.
Our team, lead by CEO Manny Villafana, has consistently innovated in the coronary device industry for 50 years. Our technologies, like heart valves and pacemakers, live on in more than 10 million patients across the globe and have created tremendous shareholder value.
Our team, lead by CEO Manny Villafana, has consistently innovated in the coronary device industry for 50 years. Our technologies, like heart valves and pacemakers, live on in more than 10 million patients across the globe and have created tremendous shareholder value.
SOLD TO ABBOTT
St.Jude heart valve
CEO Manny Villafana is the co-developer of this revolutionary heart valve that is the most commonly used prosthesis in the world in over 3 million patients.
$30 BILLION
SOLD TO BOSTON SCIENTIFIC
LITHIUM-POWERED PACEMAKER
CEO Manny Villafana is the co-inventor of the lithium-powered pacemaker that set the standard for device life-span and safety in the pacemaker industry.
$27 BILLION
$30 Billion
St. Jude Heart Valve
Sold To Abbott
CEO Manny Villafana is the co-developer of this revolutionary heart valve that is the most commonly used prosthesis in the world in over 3 million patients.
$27 Billion
Lithium-Powered Pacemaker
Sold To Boston Scientifi
CEO Manny Villafana is the co-inventor of the lithium-powered pacemaker that set the standard for device life-span and safety in the pacemaker industry.
John Babitt
Partner, Life Sciences
Ernst & Young
“I can’t say enough about Manny and his team. We have worked together for years on creating better patient outcomes through technology, and he never ceases to amaze me. I am excited to be along for the journey of Medical 21 to help them reinvent how heart bypass surgery gets done across the world.”
David Joyce, M.D.
Director of Cardiac Transplantation Medical College of Wisconsin
“I have seen first-hand the problems connected to Coronary Artery Bypass Grafts in my time with Harvard Medical School, Stanford University, and Johns Hopkins. Manny and team are dedicated to eliminating the problems of grafting and creating better outcomes for both patients and surgeons.”
Backed by Industry Leaders
Our skilled and knowledgeable advisory board provides the expertise to bring our revolutionary technology to surgeons and patients worldwide. Visit our website for a full list of board members.
Ready to invest in pioneers of heart tech?
Nearly 1 million people undergo heart bypass each year – the surgery is painful, invasive, and recovery times are drawn out. Medical 21 aims to replace the current procedure with their transformative artificial biocompatible artery technology, MAVERICS.
- +1-952-221-3104
- 15070 23rd Ave North, Minneapolis, MN 55447
Medical 21, Inc
The Medical 21 artificial graft is not yet FDA approved or cleared. For investigational use only. Not yet available for commercial sale.
The offering will be made only by means of an offering circular. An offering statement regarding this offering has been filed with the SEC. The SEC has qualified that offering statement which only means that the company may make sales of the securities described by that offering statement. It does not mean that the SEC has approved, passed upon the merits or passed upon the accuracy or completeness of the information in the offering statement. The securities offered by the company are highly speculative. Investing in shares of common stock of the company involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue. You may obtain a copy of the Form 1-A offering circular that is part of said offering statement here. You should read the offering circular before making any investment.
The offering materials and this letter may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements, which constitute forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.